News

Medical Dialogues7h
Itepekimab met primary endpoint in one of two COPD phase 3 studies: Sanofi, Regeneron
Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faced a turbulent week as its shares plunged 17%, despite announcing ...